Verapamil ER (Verapamil HCl) Patent Expiration, LOE Window & CMS Spending

Verapamil ER (Verapamil HCl) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 10 AB generics, $34.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$34.6M
2024 Medicare Part D Spend$31.7M
2024 Medicaid Spend$2.9M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 377.0% 2-yr change)